Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNG036
MIFTS: 48

Bone Giant Cell Tumor

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Giant Cell Tumor

About this section

MalaCards integrated aliases for Bone Giant Cell Tumor:

Name: Bone Giant Cell Tumor 12 15 17
Giant Cell Tumor of Bone 12 52 58 36 43 71
Osteoclastoma 12 52 58 54
Gct of Bone 52 58
Giant Cell Neoplasm of Bone 12
Giant Cell Myeloma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:4305
KEGG 36 H01470
MeSH 43 D018212
NCIt 49 C121932
SNOMED-CT 67 57500000
ICD10 via Orphanet 33 D48.0
UMLS via Orphanet 72 C0206638
Orphanet 58 ORPHA363976
UMLS 71 C0206638
Sources

Summaries for Bone Giant Cell Tumor

About this section
KEGG : 36 Giant-cell tumor of bone (GCTB) is a rare osteolytic tumor of the bone. Although classified as a benign tumor, GCTB is characterized by local aggressiveness and risk of local recurrence. Its name is derived from the numerous multinucleated giant cells found within the tumor, which are principally responsible for the extensive bone resorption that is characteristic of GCTB. However, the neoplastic components of GCTB are the spindle-like stromal cells, which produce RANKL that recruits monocytic osteoclast precursors from blood to the tumor, and stimulates differentiation into multinucleated giant cells. Recently, denosumab (RANKL inhibitor) has become a new treatment option for locally advanced GCTB.

MalaCards based summary : Bone Giant Cell Tumor, also known as giant cell tumor of bone, is related to bone giant cell sarcoma and epulis, and has symptoms including pain An important gene associated with Bone Giant Cell Tumor is ACP5 (Acid Phosphatase 5, Tartrate Resistant), and among its related pathways/superpathways are Presynaptic function of Kainate receptors and RANK Signaling in Osteoclasts. The drugs Denosumab and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include bone, monocytes and lung, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A giant cell tumor and bone cancer and bone tissue neoplasm that results in the presence of multinucleated giant cells (osteoclast-like cell).

Wikipedia : 74 Giant-cell tumor of the bone (GCTOB), is a relatively uncommon tumor of the bone. It is characterized by... more...

Sources

Related Diseases for Bone Giant Cell Tumor

About this section

Diseases related to Bone Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
# Related Disease Score Top Affiliating Genes
1 bone giant cell sarcoma 31.9 USP6 SH3BP2 H3-3B H3-3A
2 epulis 30.9 SERPINA3 CD68
3 aneurysmal bone cysts 30.5 USP6 TNFSF11 TNFRSF11A CALCA
4 fibroma 30.4 USP6 SERPINA3 CD68
5 fibrous dysplasia 30.3 SPP1 SH3BP2 CALCA
6 osteomyelitis 30.3 TNFSF11 CTSK CALCA ACP5
7 bone inflammation disease 30.2 TNFSF11 TNFRSF11B SERPINA3 ACP5
8 villonodular synovitis 30.1 TNFSF11 CD68 ACP5
9 telangiectatic osteogenic sarcoma 30.1 USP6 H3-3B H3-3A
10 osteonecrosis 30.0 TNFSF11 TNFRSF11B PTH ACP5
11 osteomalacia 30.0 TNFSF11 PTH CALCA
12 grade iii astrocytoma 30.0 THBS1 H3-3B H3-3A CTSB
13 multicentric carpotarsal osteolysis syndrome 29.9 TNFSF11 TNFRSF11B TNFRSF11A
14 malignant giant cell tumor 29.9 H3-3B H3-3A CD68
15 cherubism 29.8 USP6 TNFSF11 SH3BP2 CALCA
16 osteogenic sarcoma 29.8 TNFSF11 TNFRSF11B SPP1 PTH CALCRL
17 secondary hyperparathyroidism 29.8 TNFRSF11B PTH CALCA ACP5
18 chondroblastoma 29.7 TNFSF11 SERPINA3 H3-3B H3-3A
19 primary hyperparathyroidism 29.7 TNFSF11 TNFRSF11B PTH CALCA
20 hyperparathyroidism 29.6 TNFSF11 TNFRSF11B PTH CALCA ACP5
21 arthritis 29.5 TNFSF11 TNFRSF11A PTH CTSK ACP5
22 synovitis 29.5 TNFSF11 TNFRSF11B CD68 ACP5
23 connective tissue benign neoplasm 29.4 USP6 SERPINA3 PTH CD68
24 bone resorption disease 29.2 TNFSF11 TNFRSF11B TNFRSF11A SPP1 PTH CTSK
25 endosteal hyperostosis, autosomal dominant 29.2 TNFSF11 TNFRSF11B SH3BP2 PTH CTSK ACP5
26 bone cancer 29.0 TNFSF11 TNFRSF11B TNFRSF11A SERPINA3 CALCA
27 pigmented villonodular synovitis 29.0 TNFSF11 TNFRSF11B SERPINA3 CD68 CALCR ACP5
28 mammary paget's disease 28.9 TNFSF11 TNFRSF11B TNFRSF11A PTH CTSK CALCA
29 osteopetrosis 28.7 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCR CALCA
30 paget's disease of bone 28.3 ZNF687 TNFSF11 TNFRSF11B TNFRSF11A PTH CALCA
31 bone disease 28.2 TNFSF11 TNFRSF11B TNFRSF11A SPP1 PTH CTSK
32 giant cell tumor 27.9 ZNF687 TNFSF11 TNFRSF11B TNFRSF11A SERPINA3 H3-3B
33 giant cell reparative granuloma 26.7 USP6 TNFSF11 TNFRSF11A SH3BP2 SERPINA3 PTH
34 paget disease of bone 6 11.3
35 clear cell adenoma 10.4 PTH CALCR
36 diffuse intrinsic pontine glioma 10.4 H3-3B H3-3A
37 adult brain stem glioma 10.4 H3-3B H3-3A
38 histiocytoma 10.3
39 fibrous histiocytoma 10.3
40 undifferentiated pleomorphic sarcoma 10.3
41 nodular tenosynovitis 10.3 SERPINA3 CD68
42 congenital epulis 10.3 SERPINA3 CD68
43 spinal cord astrocytoma 10.3 H3-3B H3-3A
44 malignant fibroxanthoma 10.3
45 pilocytic astrocytoma of cerebellum 10.3 H3-3B H3-3A
46 xanthogranulomatous pyelonephritis 10.3 SERPINA3 CD68
47 cerebellar astrocytoma 10.3 SERPINA3 H3-3B
48 hypercalcemia, infantile, 1 10.3 PTH CALCA
49 inflammatory mfh 10.3 SERPINA3 CD68
50 reticulohistiocytic granuloma 10.3 SERPINA3 CD68

Graphical network of the top 20 diseases related to Bone Giant Cell Tumor:



Diseases related to Bone Giant Cell Tumor
Sources

Symptoms & Phenotypes for Bone Giant Cell Tumor

About this section

UMLS symptoms related to Bone Giant Cell Tumor:


pain

MGI Mouse Phenotypes related to Bone Giant Cell Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 CALCRL CTSB CTSK H3-3B PTH SH3BP2
2 hematopoietic system MP:0005397 10.03 CALCR CALCRL CD68 CTSK PTH SH3BP2
3 craniofacial MP:0005382 9.97 CTSK PTH SH3BP2 SPP1 THRA TNFRSF11A
4 immune system MP:0005387 9.97 CALCR CALCRL CD68 CTSB CTSK PTH
5 digestive/alimentary MP:0005381 9.87 CALCRL CTSB CTSK SH3BP2 THBS1 THRA
6 limbs/digits/tail MP:0005371 9.61 CALCR CTSK PTH SH3BP2 THBS1 THRA
7 skeleton MP:0005390 9.36 CALCR CD68 CTSK PTH SH3BP2 SPP1
Sources

Drugs & Therapeutics for Bone Giant Cell Tumor

About this section

Drugs for Bone Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4 615258-40-7
2 Antibodies, Monoclonal Phase 4
3 Antibodies Phase 4
4 Immunoglobulins Phase 4
5 Immunoglobulin G Phase 4
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Ethanol Approved Phase 3 64-17-5 702
8
Phenol Approved, Experimental Phase 3 108-95-2 996
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Analgesics Phase 3
11 Liver Extracts Phase 3
12 Cola Phase 3
13 Narcotics Phase 3
14 Anesthetics Phase 3
15 Anesthetics, General Phase 3
16 Analgesics, Opioid Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Central Nervous System Depressants Phase 3
19 Anesthetics, Intravenous Phase 3
20 Polymethyl Methacrylate Phase 3
21 Diphosphonates Phase 3
22
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
23
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
24
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
25
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
26
Zoledronic Acid Approved Phase 2 118072-93-8 68740
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
28
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
29 Micronutrients Phase 2
30 Trace Elements Phase 2
31 Vitamins Phase 2
32 Nutrients Phase 2
33 Calciferol Phase 2
34 Hormones Phase 2
35 Protein Kinase Inhibitors Phase 2
36 Interleukin-2 Phase 2
37 Anti-Infective Agents Phase 2
38 Anti-Retroviral Agents Phase 2
39 Analgesics, Non-Narcotic Phase 2
40 Antiviral Agents Phase 2
41 Antimetabolites Phase 2
42 Anti-HIV Agents Phase 2
43 Vidarabine Phosphate Phase 2
44 Pharmaceutical Solutions Phase 1, Phase 2
45
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
46
Cyclophosphamide Approved, Investigational Early Phase 1 50-18-0, 6055-19-2 2907
47
Calcium Approved, Nutraceutical 7440-70-2 271
48 Calcium, Dietary
49 Calcium Supplement
50 Alkylating Agents Early Phase 1

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
2 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
3 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
5 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone Completed NCT00396279 Phase 2
6 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed NCT00680992 Phase 2 Denosumab
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts Completed NCT03415477 Phase 1, Phase 2 Denosumab (Xgeva)
9 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
10 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
11 Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study Terminated NCT00889590 Phase 2 Zoledronic acid
12 Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Terminated NCT01564121 Phase 1, Phase 2 acid Zoledronic
13 Il Tumore a Cellule Giganti Delle estermità Completed NCT02996734
14 Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series Recruiting NCT04002817
15 Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China：Correlation Between Recurrence and Drug Withdrawl Not yet recruiting NCT03358212 Denosumab
16 Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide

Search NIH Clinical Center for Bone Giant Cell Tumor

Cochrane evidence based reviews: giant cell tumor of bone

Sources

Genetic Tests for Bone Giant Cell Tumor

About this section
Sources

Anatomical Context for Bone Giant Cell Tumor

About this section

MalaCards organs/tissues related to Bone Giant Cell Tumor:

40
Bone, Monocytes, Lung, Breast, Pancreas, Liver, Thyroid
Sources

Publications for Bone Giant Cell Tumor

About this section

Articles related to Bone Giant Cell Tumor:

(show top 50) (show all 1080)
# Title Authors PMID Year
1
[Evaluation of total scapular arthroplasty after total scapulectomy for scapular tumors]. 61
32030948 2020
2
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. 61
31784095 2020
3
Simvastatin Possesses Antitumor and Differentiation-Promoting Properties That Affect Stromal Cells in Giant Cell Tumor of Bone. 61
31471919 2020
4
Implanted β-Tricalcium Phosphate Blocks Can Function as a Placeholder in Recurrent Giant Cell Tumor of Bone. 61
32015922 2020
5
Curettage as first surgery for bone giant cell tumor : adequate surgery is more important than oncology training or surgical management by high volume specialized teams. 61
31520122 2020
6
Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. 61
31651524 2020
7
Functional Outcomes After Sauve-Kapandji Arthrodesis. 61
31948706 2020
8
Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region. 61
31950466 2020
9
Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience. 61
31862519 2019
10
Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone. 61
31762217 2019
11
Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. 61
31285528 2019
12
Denosumab Therapy Obscures Histological Features of Giant Cell Tumor of Bone. 61
31665371 2019
13
Survival and prognosis in malignant giant cell tumor of bone: A population-based analysis from 1984 to 2013. 61
31667061 2019
14
Epidemiologic Characteristics, Clinical Behavior, and Outcome of the Giant Cell Tumor of the Bone: A Retrospective Single-center Study. 61
31970259 2019
15
A case of pelvic giant cell tumor of bone, complete remission with denosumab: long duration of response. 61
31743134 2019
16
Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report. 61
31725619 2019
17
Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review. 61
31794487 2019
18
Present day controversies and consensus in curettage for giant cell tumor of bone. 61
31736607 2019
19
Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. 61
31748824 2019
20
Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. 61
31768625 2019
21
Role of intravenous zoledronic acid in management of giant cell tumor of bone- A prospective, randomized, clinical, radiological and electron microscopic analysis. 61
31736608 2019
22
Surgical resection and reconstructive techniques using autologous femoral head bone-grafting in treating partial acetabular defects arising from primary pelvic malignant tumors. 61
31627719 2019
23
Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. 61
31687646 2019
24
Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. 61
30877429 2019
25
Plasma metabolite profiling reveals potential biomarkers of giant cell tumor of bone by using NMR-based metabolic profiles: A cross-sectional study. 61
31577769 2019
26
Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images. 61
30859281 2019
27
In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. 61
31233932 2019
28
A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities. 61
31253385 2019
29
Retrospective Audit of Various Surgical Modalities Adopted for Giant Cell Tumor in a Rural Tertiary Cancer Center. 61
31496597 2019
30
Reconstruction with β-tricalcium phosphate for giant cell tumor of the talus. 61
31743864 2019
31
Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab. 61
31475058 2019
32
A posterior approach for curettage in giant cell tumor of bone in the proximal fibula. 61
31548873 2019
33
Validation of Fluorescence in situ Hybridization Testing of USP6 Gene Rearrangement for Diagnosis of Primary Aneurysmal Bone Cyst. 61
31611201 2019
34
Clinical Significance of MRI and Pathological Features of Giant Cell Tumor of Bone Boundary. 61
31422584 2019
35
[The study of the value of H3F3A G34W immunohistochemical staining in the diagnosis of giant cell tumor of bone]. 61
31288308 2019
36
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. 61
30844887 2019
37
Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. 61
31040253 2019
38
Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed? 61
31508313 2019
39
Morphologic Changes After Denosumab Therapy in Patients with Giant Cell Tumor of the Spine: Report of Four Cases and a Review of the Literature. 61
30926552 2019
40
Similar local recurrence but better function with curettage versus resection for bone giant cell tumor and pathological fracture at presentation. 61
30734307 2019
41
Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review. 61
31242985 2019
42
Intra-articular ectopic ossification associated with denosumab administration for giant cell tumor of bone with intra-articular pathological fracture. 61
28109658 2019
43
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. 61
30740297 2019
44
Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells. 61
30742944 2019
45
Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway. 61
31015476 2019
46
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610. 61
30796832 2019
47
The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities. 61
30961549 2019
48
Measurement of morphological parameters of giant cell tumor of bone in the knee. 61
30930988 2019
49
Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. 61
30449024 2019
50
Treatment of Massive Giant Cell Tumor of Bone of the Proximal Radius. Case Study. 61
31180037 2019
Sources

Variations for Bone Giant Cell Tumor

About this section
Sources

Expression for Bone Giant Cell Tumor

About this section
Search GEO for disease gene expression data for Bone Giant Cell Tumor.
Sources

Pathways for Bone Giant Cell Tumor

About this section

Pathways related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Presynaptic function of Kainate receptors 65
Show member pathways
 12.2 PTH CALCRL CALCR CALCA
2
RANK Signaling in Osteoclasts 63
Show member pathways
 12.2 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCR ACP5
3
G alpha (s) signalling events 65
11.92 PTH CALCRL CALCR CALCA
4
Lysosome 36
11.79 CTSK CTSB CD68 ACP5
5
Osteoclast differentiation 36
11.74 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCR ACP5
6
Rheumatoid arthritis 36
11.62 TNFSF11 TNFRSF11A PTH CTSK ACP5
7
Endochondral Ossification 1
11.47 THRA SPP1 PTH
8
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.2 TNFSF11 SPP1 PTH
9
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.88 TNFSF11 TNFRSF11B TNFRSF11A THRA SPP1 PTH
10
Osteoblast Signaling 1
10.69 TNFSF11 TNFRSF11B PTH
11
Osteoclast Signaling 1
10.64 TNFSF11 TNFRSF11B TNFRSF11A SPP1 CTSK ACP5
Sources

GO Terms for Bone Giant Cell Tumor

About this section

Cellular components related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNFSF11 TNFRSF11B THBS1 SPP1 SERPINA3 PTH
2 extracellular region GO:0005576 9.7 TNFSF11 TNFRSF11B THBS1 SPP1 SERPINA3 PTH
3 Barr body GO:0001740 9.32 H3-3B H3-3A
4 endolysosome lumen GO:0036021 9.26 CTSK CTSB
5 lysosome GO:0005764 9.1 USP6 CTSK CTSB CD68 CALCRL ACP5

Biological processes related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.89 SPP1 H3-3B H3-3A CALCA
2 osteoblast differentiation GO:0001649 9.8 SPP1 H3-3B H3-3A
3 regulation of megakaryocyte differentiation GO:0045652 9.76 THBS1 H3-3B H3-3A
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.76 PTH CALCRL CALCR CALCA
5 monocyte chemotaxis GO:0002548 9.73 TNFSF11 TNFRSF11A CALCA
6 osteoclast differentiation GO:0030316 9.69 TNFSF11 TNFRSF11A CALCR
7 response to vitamin D GO:0033280 9.63 SPP1 PTH
8 mammary gland alveolus development GO:0060749 9.62 TNFSF11 TNFRSF11A
9 muscle cell differentiation GO:0042692 9.62 H3-3B H3-3A
10 negative regulation of bone resorption GO:0045779 9.61 TNFRSF11B CALCA
11 response to magnesium ion GO:0032026 9.61 TNFRSF11B THBS1
12 negative regulation of interleukin-12 production GO:0032695 9.6 THBS1 ACP5
13 amylin receptor signaling pathway GO:0097647 9.58 CALCR CALCA
14 negative regulation of smooth muscle contraction GO:0045986 9.57 CALCRL CALCA
15 ossification GO:0001503 9.56 TNFSF11 TNFRSF11A THRA ACP5
16 TNFSF11-mediated signaling pathway GO:0071847 9.55 TNFSF11 TNFRSF11A
17 pericentric heterochromatin assembly GO:0031508 9.54 H3-3B H3-3A
18 negative regulation of dendritic cell antigen processing and presentation GO:0002605 9.52 THBS1 CD68
19 calcitonin gene-related peptide receptor signaling pathway GO:1990408 9.49 CALCRL CALCA
20 regulation of centromere complex assembly GO:0090230 9.48 H3-3B H3-3A
21 negative regulation of chromosome condensation GO:1902340 9.43 H3-3B H3-3A
22 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.4 TNFSF11 TNFRSF11A
23 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.37 TNFSF11 TNFRSF11A
24 positive regulation of bone resorption GO:0045780 9.33 TNFSF11 TNFRSF11A SPP1
25 telomeric heterochromatin assembly GO:0031509 9.32 H3-3B H3-3A
26 embryo implantation GO:0007566 9.26 SPP1 H3-3B H3-3A CALCA
27 bone resorption GO:0045453 8.92 TNFSF11 PTH CTSK ACP5

Molecular functions related to Bone Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 ZNF687 USP6 TNFSF11 TNFRSF11B TNFRSF11A THRA
2 cysteine-type endopeptidase activity GO:0004197 9.5 USP6 CTSK CTSB
3 calcitonin gene-related peptide receptor activity GO:0001635 9.16 CALCRL CALCR
4 calcitonin receptor activity GO:0004948 8.96 CALCRL CALCR
5 proteoglycan binding GO:0043394 8.8 THBS1 CTSK CTSB
Sources

Sources for Bone Giant Cell Tumor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....